Molecular structure of ABN-CBD, CAS Number: 22972-55-0
ABN-CBD (CAS 22972-55-0)
See product citations (1)
Alternate Names:
Abnormal-cannabidiol
Application:
ABN-CBD is an agonist of the novel cannabinoid receptor GPR55
CAS Number:
22972-55-0
Purity:
≥98%
Molecular Weight:
314.47
Molecular Formula:
C21H30O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ABN-CBD, or abnormal cannabidiol, is a synthetic analog of cannabidiol (CBD) that is particularly noteworthy in neuroscientific and cellular research due to its unique interaction with the G protein-coupled receptor GPR55. The interaction of ABN-CBD with GPR55 plays a significant role in the modulation of intracellular signaling pathways, particularly in relation to protein kinases. One notable effect of ABN-CBD′s activation of GPR55 is the increased phosphorylation of protein kinases. This phosphorylation is a post-translational modification that alters the activity, interactions, and functions of proteins, thereby regulating various cellular processes. The study of ABN-CBD′s effects on kinase phosphorylation can provide insights into the signaling pathways mediated by GPR55 and their implications in cellular function and behavior.
ABN-CBD (CAS 22972-55-0) References
- Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. | Mishima, K., et al. 2005. Stroke. 36: 1077-82. PMID: 15845890
- Effects of abnormal cannabidiol on oxytocin-induced myometrial contractility. | Houlihan, DD., et al. 2010. Reproduction. 139: 783-8. PMID: 20068032
- The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. | Schuelert, N. and McDougall, JJ. 2011. Neurosci Lett. 500: 72-6. PMID: 21683763
- Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. | Szczesniak, AM., et al. 2011. J Ocul Pharmacol Ther. 27: 427-35. PMID: 21770780
- Role of Endothelium in Abnormal Cannabidiol-Induced Vasoactivity in Retinal Arterioles. | Su, EN., et al. 2015. Invest Ophthalmol Vis Sci. 56: 4029-37. PMID: 26098470
- Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. | Krohn, RM., et al. 2016. J Inflamm (Lond). 13: 21. PMID: 27418880
- LH-21 and abnormal cannabidiol improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling. | Ruz-Maldonado, I., et al. 2018. Diabetes Obes Metab. 20: 930-942. PMID: 29205751
- Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control. | Matouk, AI., et al. 2018. Eur J Pharmacol. 820: 256-264. PMID: 29274332
- Abnormal Cannabidiol Modulates Vitamin A Metabolism by Acting as a Competitive Inhibitor of CRBP1. | Silvaroli, JA., et al. 2019. ACS Chem Biol. 14: 434-448. PMID: 30721022
- Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer. | Tomko, A., et al. 2019. Front Pharmacol. 10: 1124. PMID: 31611800
- Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures. | Cardinal von Widdern, J., et al. 2020. Molecules. 25: PMID: 31979350
- A molecular explanation of cardiovascular protection through abnormal cannabidiol: Involving the dysfunctional β-adrenergic and ATP-sensitive K+ channel activity in cardiovascular compromised preterm infants. | Hassan Almalki, W., et al. 2021. J Biochem Mol Toxicol. 35: e22849. PMID: 34309957
- Abnormal cannabidiol ameliorates inflammation preserving pancreatic beta cells in mouse models of experimental type 1 diabetes and beta cell damage. | González-Mariscal, I., et al. 2022. Biomed Pharmacother. 145: 112361. PMID: 34872800
Activator of:
CB1, CB2, and GPR55.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ABN-CBD, 1 mg | sc-203488A | 1 mg | $37.00 | |||
ABN-CBD, 5 mg | sc-203488B | 5 mg | $146.00 | |||
ABN-CBD, 10 mg | sc-203488 | 10 mg | $240.00 | |||
ABN-CBD, 25 mg | sc-203488C | 25 mg | $552.00 |